NPS MedicineWise is funded by the Australian Government Department of Health and Aged Care through the Quality Use of Diagnostics, Therapeutics and Pathology Program to improve the way medicines and medical tests are prescribed and used (QUM grant).
Quality use of medicines issues relating to opioids are complex and persist.
The high risk medicines: Opioid and chronic pain management program aims to sustain and amplify the impact of previous NPS MedicineWise programs relating to opioids and chronic non cancer pain, thereby contributing to ongoing improvements in health professional knowledge and practice and consumer health literacy in this area and ongoing stakeholder engagement to share learnings with relevant stakeholders.
Program facts and figures
- Program delivery: July 2021 – June 2022
- Program costs Financial Year 2020-21: $117,203
Health professional resources
- Program landing page: Opioid and chronic pain management
- MedicineWise News article and podcast to support health professional skills and knowledge in handling challenging conversations around opioid use disorder and available management options.
- Marketing communication campaign to increase health professional engagement with available opioid and pain management content and resources. This includes those developed within previous NPS MedicineWise QUM programs, and by other organisations active in this area.
Consumer resources
- Marketing communication campaign to increase consumer health literacy around opioids and pain management utilising currently available content and resources. This will include those developed within previous NPS MedicineWise programs and by other organisations active in this area.